- Home
- BNT vs INCY Comparison
BNT vs INCY Comparison
Compare BNT & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNT
- INCY
- Stock Information
- Founded
- BNT 2020
- INCY 1991
- Country
- BNT Bermuda
- INCY United States
- Employees
- BNT N/A
- INCY N/A
- Industry
- BNT
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- BNT
- INCY Health Care
- Exchange
- BNT Nasdaq
- INCY Nasdaq
- Market Cap
- BNT 15.0B
- INCY 13.0B
- IPO Year
- BNT N/A
- INCY 1993
- Fundamental
- Price
- BNT $63.80
- INCY $69.34
- Analyst Decision
- BNT
- INCY Hold
- Analyst Count
- BNT 0
- INCY 20
- Target Price
- BNT N/A
- INCY $72.75
- AVG Volume (30 Days)
- BNT 9.7K
- INCY 1.8M
- Earning Date
- BNT 08-07-2025
- INCY 07-29-2025
- Dividend Yield
- BNT 0.57%
- INCY N/A
- EPS Growth
- BNT N/A
- INCY N/A
- EPS
- BNT 2.28
- INCY 0.10
- Revenue
- BNT $14,236,000,000.00
- INCY $4,413,226,000.00
- Revenue This Year
- BNT N/A
- INCY $13.48
- Revenue Next Year
- BNT N/A
- INCY $10.37
- P/E Ratio
- BNT $27.65
- INCY $713.94
- Revenue Growth
- BNT 73.14
- INCY 17.13
- 52 Week Low
- BNT $42.31
- INCY $53.56
- 52 Week High
- BNT $64.47
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- BNT N/A
- INCY 52.44
- Support Level
- BNT N/A
- INCY $66.85
- Resistance Level
- BNT N/A
- INCY $70.62
- Average True Range (ATR)
- BNT 0.00
- INCY 1.85
- MACD
- BNT 0.00
- INCY -0.16
- Stochastic Oscillator
- BNT 0.00
- INCY 38.87
About BNT Brookfield Wealth Solutions Ltd.
Brookfield Wealth Solutions Ltd, formerly Brookfield Reinsurance Ltd operates a capital solutions business providing insurance and reinsurance services to individuals and institutions. Through its subsidiary, the company offers a broad range of insurance products and services, including life insurance and annuities, and personal and commercial property and casualty insurance. It is organized into three reporting segments: Direct Insurance, Reinsurance, and Pension Risk Transfer (PRT).
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.